دورية أكاديمية
GD2 Expression in Medulloblastoma and Neuroblastoma for Personalized Immunotherapy: A Matter of Subtype
| العنوان: | GD2 Expression in Medulloblastoma and Neuroblastoma for Personalized Immunotherapy: A Matter of Subtype |
|---|---|
| المؤلفون: | Claudia Paret, Arsenij Ustjanzew, Sara Ersali, Larissa Seidmann, Richard Jennemann, Nicole Ziegler, Khalifa El Malki, Alexandra Russo, Arthur Wingerter, Franziska Ortmüller, Angelina Bornas, Pia Charlotte Wehling, Adina Lepădatu, Malte Ottenhausen, Wilfried Roth, Clemens Sommer, Barbara Fliss, Katrin B. M. Frauenknecht, Roger Sandhoff, Jörg Faber |
| المصدر: | Cancers, Vol 14, Iss 24, p 6051 (2022) |
| بيانات النشر: | MDPI AG, 2022. |
| سنة النشر: | 2022 |
| المجموعة: | LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| مصطلحات موضوعية: | neuroblastoma, medulloblastoma, GD2, N-glycolyl GM3, racotumomab, dinutuximab, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| الوصف: | Neuroblastoma (NBL) and medulloblastoma (MB) are aggressive pediatric cancers which can benefit from therapies targeting gangliosides. Therefore, we compared the ganglioside profile of 9 MB and 14 NBL samples by thin layer chromatography and mass spectrometry. NBL had the highest expression of GD2 (median 0.54 nmol GD2/mg protein), and also expressed complex gangliosides. GD2-low samples expressed GD1a and were more differentiated. MB mainly expressed GD2 (median 0.032 nmol GD2/mg protein) or GM3. Four sonic hedgehog-activated (SHH) as well as one group 4 and one group 3 MBs were GD2-positive. Two group 3 MB samples were GD2-negative but GM3-positive. N-glycolyl neuraminic acid-containing GM3 was neither detected in NBL nor MB by mass spectrometry. Furthermore, a GD2-phenotype predicting two-gene signature (ST8SIA1 and B4GALNT1) was applied to RNA-Seq datasets, including 86 MBs and validated by qRT-PCR. The signature values were decreased in group 3 and wingless-activated (WNT) compared to SHH and group 4 MBs. These results suggest that while NBL is GD2-positive, only some MB patients can benefit from a GD2-directed therapy. The expression of genes involved in the ganglioside synthesis may allow the identification of GD2-positive MBs. Finally, the ganglioside profile may reflect the differentiation status in NBL and could help to define MB subtypes. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2072-6694 |
| Relation: | https://www.mdpi.com/2072-6694/14/24/6051; https://doaj.org/toc/2072-6694 |
| DOI: | 10.3390/cancers14246051 |
| URL الوصول: | https://doaj.org/article/b5acedd08be946fdb657d7f48b57cfa6 |
| رقم الأكسشن: | edsdoj.b5acedd08be946fdb657d7f48b57cfa6 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder كن أول من يترك تعليقا!